Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever

Purpose:  Empirical use of intravenous (IV) itraconazole (ITZ) for febrile neutropenic patients has recently been introduced in Korea. This study was designed to investigate the population pharmacokinetics (PK) of IV‐ITZ.

[1]  Stefanie Hennig,et al.  A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. , 2007, British journal of clinical pharmacology.

[2]  S. Park,et al.  Intravenous Itraconazole vs. Amphotericin B Deoxycholate for Empirical Antifungal Therapy in Patients with Persistent Neutropenic Fever , 2006, The Korean journal of internal medicine.

[3]  S. Bell,et al.  Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients , 2006, Clinical pharmacokinetics.

[4]  P. Hsueh,et al.  Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. , 2005, International journal of antimicrobial agents.

[5]  A. Glasmacher,et al.  Making sense of itraconazole pharmacokinetics. , 2005, The Journal of antimicrobial chemotherapy.

[6]  M. Boogaerts,et al.  The place for itraconazole in treatment. , 2005, The Journal of antimicrobial chemotherapy.

[7]  G. Khoschsorur,et al.  Isocratic High-Performance Liquid Chromatographic Method with Ultraviolet Detection for Simultaneous Determination of Levels of Voriconazole and Itraconazole and Its Hydroxy Metabolite in Human Serum , 2005, Antimicrobial Agents and Chemotherapy.

[8]  J. Wingard.  Empirical antifungal therapy in treating febrile neutropenic patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Klastersky.  Empirical antifungal therapy. , 2004, International journal of antimicrobial agents.

[10]  O. Sezer,et al.  Antimicrobial therapy of unexplained fever in neutropenic patients , 2003, Annals of Hematology.

[11]  J. Beijnen,et al.  Population Pharmacokinetics of Itraconazole in Thai HIV-1-Infected Persons , 2003, Therapeutic drug monitoring.

[12]  A. Schwarer,et al.  Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy , 2001, Annals of Internal Medicine.

[13]  M. Boogaerts,et al.  Pharmacokinetics and Safety of a 7-Day Administration of Intravenous Itraconazole followed by a 14-Day Administration of Itraconazole Oral Solution in Patients with Hematologic Malignancy , 2001, Antimicrobial Agents and Chemotherapy.

[14]  T. Sauerbruch,et al.  Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl‐β‐cyclodextrin oral solution or coated‐pellet capsules , 1999, Mycoses.

[15]  C. Leutner,et al.  Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole , 1999, Mycoses.

[16]  G. Cheymol,et al.  Optimisation of Itraconazole Therapy Using Target Drug Concentrations , 1998, Clinical pharmacokinetics.

[17]  G. Verhoef,et al.  Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels , 1989, Mycoses.

[18]  R. Woestenborghs,et al.  The Clinical Pharmacokinetics of Itraconazole: An Overview , 1989, Mycoses.